Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Harmony Biosciences Raises $270m; Acquires US Rights To Narcolepsy Drug

Executive Summary

Emerging US biotech Harmony Biosciences has secured $270m in financing to acquire a Phase III narcolepsy drug, which it expects to file with the FDA in 2018. 

Advertisement

Related Content

Finance Watch: Flagship Raises $824m To Speed Growth Of Its Portfolio Companies
Deal Watch: Harbour Expands Horizons Beyond China
Keeping Track: Thumbs Up For Doptelet And Palynziq, Thumbs Down For Methylene Blue MMX And Meloxicam
Biopharma Quarterly Deal-making Statistics, Q4 2017
Start-Up Quarterly Statistics: 2017 Fundraising Ends Better Than It Began
Venture Funding Deals: From ADC To Y-mAbs, Capital Flows For New Platforms, Novel Approaches

Topics

Advertisement
UsernamePublicRestriction

Register

SC099621

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel